ArticleInsights into imaging2026
PNET-PRISM: a multicenter-validated radiomics nomogram for noninvasive grading of pancreatic neuroendocrine tumors.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate preoperative grading of pancreatic neuroendocrine tumors (PNETs) is essential for optimal treatment selection, yet endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) yields inadequate tissue in up to 40% of cases and carries procedural risks, necessitating reliable noninvasive alternatives. MATERIALS AND
methodsThis multicenter retrospective study included 407 surgically confirmed PNET patients across training (n = 244), validation (n = 106), and external test (n = 57) cohorts. We developed a pancreatic radiomics integrated scoring model for PNET (PNET-PRISM), integrating multidimensional CT radiomics features from intratumoral, peritumoral, habitat, and deep learning domains using automated segmentation. A multidimensional deep learning radiomics score (M-DLR Score) was constructed from 13,542 features and combined with clinical variables for preoperative grade prediction.
resultsPNET-PRISM demonstrated robust performance with AUCs of 0.92, 0.89, and 0.87 in training, validation, and external test sets, respectively, significantly outperforming clinical-only models (ΔAUC = 0.15-0.22, all p < 0.001). The model achieved perfect sensitivity (100%) in external validation and provided accurate grading in 13 of 25 patients (52%) where EUS-FNA yielded insufficient tissue. Net Reclassification Improvement analysis demonstrated significant improvement over clinical models across all datasets (NRI = 0.318-0.406, p ≤ 0.070). M-DLR Score stratification showed a significant association with progression-free survival (HR = 2.050, 95% CI: 1.484-2.833, p < 0.001).
conclusionsThis validated radiomics-based nomogram serves as a powerful noninvasive decision-support tool for PNET risk stratification, effectively complementing EUS-FNA limitations and enabling optimized treatment pathways, particularly when biopsy is contraindicated or nondiagnostic. CRITICAL RELEVANCE STATEMENT: This CT-based radiomics nomogram reliably grades pancreatic neuroendocrine tumors (PNETs) and predicts prognosis. This study addresses endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) limitations and advances clinical radiology by enabling safer triage and personalized management when tissue diagnosis is uncertain or unavailable. KEY POINTS: A CT-based pancreatic radiomics integrated scoring model for PNET (PNET-PRISM) helps when endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) fails. In 407 patients, PRISMPNET-PRISM achieved a high area under the curve (AUC) and 100% external sensitivity for triage. The multidimensional deep learning radiomics (M-DLR) score stratified progression-free survival (hazard ratio (HR) ≈ 2.05) and rescued nondiagnostic biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.